This is a rewiev concerning contemporary treatment's knowledge of multiple myeloma. No difference in surviva was noted between patients given a single alkylating agent and those given a combination of alkylating agents. The highest response rates reported for patients resistant to alkylating agents have been with VAD (vincristin, adriamycin, dexamethason). The administration of alfa interferon has brought an improvement to the therapy. The supporting therapy with calcitonin and biphosphonates is also discussed.
Therapy of the multiple myeloma
